Atlas Trials

Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study

Clinical trial NCT05231863 · UNKNOWN

Trial details

NCT number
NCT05231863
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Study type
OBSERVATIONAL
Breast Cancer
Start date
2019-08-01
Primary completion
2022-12-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.